“Insulin used to cost around $500 for one box, and now it’s down to somewhere around $150, $200, so they’ve really dropped ...

U.S. officials are warning about a potentially life-threatening issue with smartphone apps that help manage diabetes.

A randomized controlled trial demonstrated a significantly reduced incidence of type 2 diabetes among individuals with metabolic syndrome who received daily metformin with or without a Mediterranean ...

There's currently no cure for dementia. Although some recently developed drugs show promise in slowing the progress of the ...

New research found that over half of people with type 2 diabetes in the Americas may be deficient in essential nutrients, ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...

"Yo-yo" dieting --- repeatedly losing and gaining weight -- can significantly increase risk of kidney disease among people ...

Use of a sodium-glucose cotransporter 2, or SGLT2, inhibitor combined with calorie restriction resulted in greater rates of type 2 diabetes remission compared with calorie restriction alone, according ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...